He serves as Director of the Columbia NYSTEM Chemical Probe Synthesis Facility, and co-Director of the Columbia High-Throughput Screening Center. His research involves the discovery of precision medicines that can be used to understand and treat cancer and neurodegeneration, with a focus on mechanisms governing cell death. These interdisciplinary investigations have led to new methods of small molecule drug discovery, and the discovery of drug candidates that act through a new form of cell death.